142,443 Shares in Harmony Biosciences Holdings, Inc. $HRMY Purchased by Man Group plc

Man Group plc bought a new stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 142,443 shares of the company’s stock, valued at approximately $5,186,000. Man Group plc owned about 0.24% of Harmony Biosciences as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Amundi raised its holdings in shares of Harmony Biosciences by 115.6% in the 1st quarter. Amundi now owns 39,668 shares of the company’s stock worth $1,229,000 after purchasing an additional 21,266 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Harmony Biosciences by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,651 shares of the company’s stock valued at $752,000 after purchasing an additional 984 shares during the period. Empowered Funds LLC purchased a new stake in Harmony Biosciences in the first quarter worth $2,330,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Harmony Biosciences by 53.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 95,389 shares of the company’s stock worth $3,166,000 after buying an additional 33,058 shares during the last quarter. Finally, Cetera Investment Advisers raised its stake in shares of Harmony Biosciences by 9.8% in the second quarter. Cetera Investment Advisers now owns 8,404 shares of the company’s stock valued at $266,000 after buying an additional 748 shares during the period. 86.23% of the stock is owned by institutional investors.

Harmony Biosciences Price Performance

Shares of NASDAQ HRMY opened at $39.21 on Monday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 3.45 and a current ratio of 3.48. Harmony Biosciences Holdings, Inc. has a fifty-two week low of $25.52 and a fifty-two week high of $40.87. The stock has a market cap of $2.28 billion, a PE ratio of 12.73, a price-to-earnings-growth ratio of 0.36 and a beta of 0.96. The stock has a fifty day moving average of $36.88 and a 200-day moving average of $32.79.

Harmony Biosciences (NASDAQ:HRMY) last issued its quarterly earnings data on Tuesday, August 4th. The company reported $1.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.96 by $0.32. Harmony Biosciences had a return on equity of 20.06% and a net margin of 18.88%.The business had revenue of $261.28 million for the quarter, compared to analysts’ expectations of $250.77 million. During the same quarter in the prior year, the firm posted $0.92 EPS. The firm’s quarterly revenue was up 30.3% on a year-over-year basis. Equities research analysts anticipate that Harmony Biosciences Holdings, Inc. will post 3.77 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on HRMY shares. Needham & Company LLC increased their price target on Harmony Biosciences from $45.00 to $50.00 and gave the stock a “buy” rating in a research note on Tuesday, August 4th. Truist Financial boosted their price objective on Harmony Biosciences from $29.00 to $34.00 and gave the company a “hold” rating in a research note on Wednesday, August 5th. HC Wainwright reaffirmed a “buy” rating and set a $55.00 price objective on shares of Harmony Biosciences in a report on Thursday, July 16th. Oppenheimer reiterated an “outperform” rating and set a $70.00 target price on shares of Harmony Biosciences in a research report on Tuesday, August 4th. Finally, Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $39.00 price target on shares of Harmony Biosciences in a research report on Wednesday, August 5th. Five equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $47.11.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc is a commercial?stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.